

Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet

1

OF

4

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JE</i>	4,309,404	1/5/1982	DeNeale et al.	424	21	
<i>JE</i>	4,309,406	1/5/1982	Guley et al.	424	21	
<i>JE</i>	4,556,552	12/3/1985	Porter et al.	424	32	
<i>JE</i>	4,704,295	11/3/1987	Porter et al.	427	3	
<i>JE</i>	5,220,007	12/21/1993	Cho-Chung	424	450	
<i>JE</i>	5,271,941	12/21/1993	Cho-Chung	424	450	
<i>JE</i>	5,470,967	11/28/1995	Huie et al.	536	24.3	
<i>JE</i>	5,652,355	7/29/1997	Metlev et al.	536	24.5	
<i>JE</i>	5,969,117	10/19/1999	Agrawal	536	22.1	

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>JE</i> ✓	0 490 077 A1	10/21/1991	EP	C12N 15	11		X
<i>JE</i> ✓	94/17189	8/4/1994	WO	C12N 15	54		X
<i>JE</i> ✓	94/23028	10/13/1994	WO	C12N 15	11		X
<i>JE</i> ✓	96/16976	6/6/1996	WO	CO7H 21	02		X
<i>JE</i>	96/31600	10/10/1996	WO	C12N 15	11		X
<i>JE</i>	97/11171	3/27/1997	WO	C12N 15	11		X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)


<i>JE</i>	A1	Agrawal and Goodchild, "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation." <i>Tet. Lett.</i> , Vol. 28, No. 31, pp. 3539-3542 (1987)
<i>JE</i>	A2	Agrawal and Zhang, "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animal" In: Antisense Research and Application, S. T. Crooke, ed., Handbook of Experimental Pharmacology, Springer, Berlin, pp. 525-543 (1998)
<i>JE</i>	A3	Agrawal et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 85, pp. 7079-7083 (1988)
<i>JE</i>	A4	Agrawal et al., "Antisense oligonucleotides as antiviral agents." <i>Trends Biotechnol.</i> , Vol. 10, pp. 152-158 (1992)
<i>JE</i>	A5	Beaucage, Serge L., "Oligodeoxyribonucleotides Synthesis," <i>Meth. Mol. Biol.</i> , Vol. 20, pp. 33-61 (1993) <i>Humana Press, Totowa, N.J.</i> in <i>Protocols for Oligonucleotide Analogs</i>
<i>JE</i>	A6	Beaucage, in Protocols for Oligonucleotides and Analogs: Synthesis and Properties Agrawal (ed.), Humana Press, Totowa, NJ, pp. 53-62 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

duplicate
of A5
reference



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet

2

OF


4

	B1	Beebe et al. "Cyclic Nucleotides-Dependent Protein Kinases" in The Enzymes: Control by Phosphorylation, Academic Press, NY, Vol. 17, No. A, pp. 43-111 (1986)
	B2	Bergot et al. "Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography." <i>J. Chromatog.</i> , Vol. 559, pp. 35-42 (1992)
	B3	Buckheit et al. "Characterization of an HIV-1 Isolated Displaying an Apparent Absence of Virion-Associated Reverse Transcriptase Activity." <i>AIDS Research and Human Retroviruses</i> , Vol. 7, No. 3, pp. 295-302 (1991)
	B4	Cadd et al., "Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides." <i>J. Biol. Chem.</i> , Vol. 265, pp. 19502-19506 (1990)
	B5	Cambell et al., "Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid." <i>Biochem. Biophys. Meth.</i> , Vol. 20, pp. 259-267 (1990)
	B6	Cheng et al., "An active twenty-amino-acid-residue peptide derived from the inhibitor protein of the cyclic AMP-dependent protein kinase." <i>Biochem J.</i> , Vol. 231, No. 3, pp. 655-661 (1985)
	B7	Cho-Chung, YS, "Hypothesis. Cyclic AMP and its receptor protein in tumor growth regulation in vivo." <i>J. Cyclic Nucleotide Res.</i> , Vol. 6, pp. 163-167 (1980)
	B8	Cho-Chung, YS, "Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy." <i>Cancer Res.</i> , Vol. 50, pp. 7093-7100 (1990)
	B9	Cho-Chung et al., <i>Curr. Opin. Thera. Patents</i> , Vol. 3, pp. 1737-1750 (1993)
	B10	Ciardiello and Tortora, "Interactions between the Epidermal Growth Factor Receptor and Type I Protein Kinase A: Biological Significance and Therapeutic Implications." <i>Clin. Cancer Res.</i> , Vol. 4, pp. 821-828 (1998)
	B11	Clegg et al., "Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase" <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 85, pp. 3703-3707 (1988)
	B12	Ekanager et al., "The Separate Estimation of cAMP Intracellularly Bound to the Regulatory Subunits of Protein Kinase I and II in Glucagon-stimulated Rat Hepatocytes." <i>J. Biol. Chem.</i> , Vol. 260, pp. 3393-3401 (1985)
		Fokman, Judah, "Tumor Angiogenesis." In: J. Mendelsohn et al., eds., The Molecular Basis of Cancer, pp. 206-232, Philadelphia: WB Saunders (1995)
	B14	Froehler, Brian C., "Deoxynucleoside H-Phosphonate Diester Intermediates in the Synthesis of Internucleotide Phosphate Analogues." <i>Tetrahedron Lett.</i> , Vol. 27, pp. 5575-5578 (1986)
	B15	Galbraith et al. "Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey" <i>Antisense Research and Development</i> , Vol. 4, pp. 201-206 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Sub For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet

3

OF

4


See
A9 on
5-19-01
IDS
B1 of
5-19-01
B2
5-19-01
IDS

	C1	Goldstein et al., "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model." <i>Clin. Cancer Res.</i> , Vol. 1, No. 11, pp. 1311-1318 (1995)
	C2	Goldstein et al., "Bioconjugate Chemistry." <i>Bioconjugate Chem.</i>, Vol. 1, pp. 165-187 (1990)
	C3	Henry et al. <i>Pharm. Res.</i> 11: PPDM8082 (1994)
	C5	Iyer et al., "A Novel Nucleoside Phosphoramidite Synthon Derived From 1R, 2iS - Ephedrine." <i>Tetrahedron Asymmetry</i> , Vol. 6, pp. 1051-1054 (1995)
	C6	Kabat and Mayer (ed.), "Sequences of Proteins and Nucleic Acids," Springfield, IL, Thomas, p. 125
	C7	Kemp et al., "Role of Multiple Basis Residues in Determining the Substrated Specificity of Cyclic AMP-dependent Protein Kinase." <i>J. Biol. Chem.</i> , Vol. 252, pp. 4888-4894 (1977)
	C8	Krebs, Edwin, "Protein Kinases" <i>Curr. Topics Cell. Regul.</i> , Vol. 5, pp. 99-133 (1972)
	C9	Loda et al., "Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas." <i>Nature Medicine</i> , Vol. 3, pp. 231-234 (1997)
	C10	Lohmann and Walter, "Regulations of the Cellular and Subcellular Concentrations and Distribution of Cyclic Nucleotide-Dependent Protein Kinases." <i>Advances in Cyclic Nucleotide and Protein Phosphorylation Research</i> , Vol. 18, pp. 63-117, Raven, New York, (1984)
	C11	Lu et al., "In vivo stability, pharmacokinetics, and metabolism of a "hybrid" oligonucleotide phosphorothioates in rats" <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 36, p. 411 (Abstract 2450) (1995)
	C12	Mantel, "Evaluation of survival data and two new rank order statistics arising in its consideration." <i>Cancer Chem. Rep.</i> , Vol. 50, No. 3, pp. 163-170 (1966)
	C13	Monia et al., "Evaluation of 2' -Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression." <i>Journal of Biological Chemistry</i> , Vol. 268, pp. 14514-14522 (1993)
	C14	Nara and Fischinger, "Quantitative infectivity assay for HIV-1 and HIV-2." <i>Nature</i> , Vol. 332, pp. 469-470 (1988)
	C15	Nesterova and Cho-Chung, "A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth." <i>Nature Med.</i> , Vol. 1, pp. 528-533 (1995)
	C16	Nigg et al., "Cyclic-AMP-Dependent Protein Kinase Type II Is Associated with the Golgi Complex and with Centrosomes." <i>Cell</i> , Vol. 41, pp. 1039-1051 (1985)
	C17	Øyen et al., "A unique mRNA species for a regulatory subunit of cAMP-dependent protein kinase is specifically induced in haploid germ cells." <i>FEBS Lett.</i> , Vol. 229, pp. 391-394 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-050CP2Application Number
09/412,947Applicant
AgrawalFiling Date
October 05, 1999Group Art Unit
1635

Sheet 4 OF 4

JE	D1	Padmapriya et al., "Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide Phosphorothioates." <i>Antisense Res. & Dev.</i> , Vol. 4, pp. 185-199 (1994)
JE	D2	Pisetsky et al., "Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides" <i>Molecular Biology Report</i> , Vol. 18, pp. 217-221 (1993)
JE	D3	Remington's Pharmaceutical Sciences (18th ed.) Genarro, ed., Mack Publishing Co., Easton, PA, (1990)
JE	D4	Rohlf et al., "8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells." <i>J. Biol. Chem.</i> , Vol. 268, pp. 5774-5782 (1993)
JE	D5	Roskoski, Robert, "Assays of Protein Kinase" <i>Methods Enzymol.</i> , Vol. 99, pp. 3-6 (1983)
JE	D6	Salomon, "Epidermal growth factor-related peptides and their receptors in human malignancies" <i>Crit. Rev. Oncol. Hematol.</i> , Vol. 19, pp. 183-232 (1995)
JE	D7	Slapak et al. in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., NY, pp. 1826-1850 (1994)
JE	D8	Tagliaferri et al., "Reverse Transformation of Harvey Murine Sarcoma Virus-transformed NIH/3T3 Cells by Site-selective Cyclic AMP Analogs." <i>J. Biol. Chem.</i> , Vol. 263, pp. 409-416 (1988)
JE	D9	Tortora et al., "An antisense oligodeoxynucleotide targeted against the type II β regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 87, pp. 705-708 (1990)
JE	D10	Uhler et al. "Expression of cDNAs for two isoforms of the catalytic subunit of cAMP-dependent protein kinase." <i>J. Biol. Chem.</i> , Vol. 262, pp. 15202-15207 (1987)
[REDACTED]		
JE	D12	Weidner, "Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors" <i>Breast Cancer Res. Treat.</i> , Vol. 36, pp. 169-180 (1995)
JE	D13	Yu et al., "Hybrid Oligonucleotides: Synthesis, Biophysical Properties, Stability Studies, and Biological Activity" <i>Bioorganic & Medicinal Chemistry</i> , Vol. 4, No. 10, pp. 1685-1692 (1996)
JE	D14	Zamecnik and Stephenson, "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 75, pp. 280-284 (1978)
[REDACTED]		
JE	D16	Zhao et al., "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation" <i>Biochemical Pharmacology</i> , Vol. 51., pp. 173-182 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.